Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination With Carboplatin and Etoposide Chemotherapy Versus Carboplatin and Etoposide Alone in Chemotherapy Naive Patients With Extensive-Stage Small Cell Lung Cancer.

Next Previous
X
Search
Trial Profile

A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination With Carboplatin and Etoposide Chemotherapy Versus Carboplatin and Etoposide Alone in Chemotherapy Naive Patients With Extensive-Stage Small Cell Lung Cancer.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palifosfamide (Primary) ; Carboplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MATISSE
  • Sponsors Alaunos Therapeutics

    • Most Recent Events

    • 18 Dec 2021 This trial has been completed in Italy (Global end date: 02 Dec 2014).
    • 16 Dec 2021 This trial has been completed in France (Global end date: 02 Dec 2014).
    • 21 Jun 2019 Trial has been completed in UK, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top